What's happening
This bill establishes new patient safety and quality assurance requirements for how insurer-designated pharmacies distribute medications for administration at healthcare facilities.
Why it matters
Reduces “white bagging” risks. By prohibiting insurers from requiring patients to pick up medications from insurer-designated pharmacies and transport them to healthcare facilities, the bill aims to limit safety and liability risks linked to improper drug handling and storage by non-professional intermediaries.
Strengthens provider oversight and patient safety. The bill requires formal agreements between insurers and healthcare providers that cover medication handling, storage, cold chain logistics, delivery, and emergency access to pharmacists or nurses—directly addressing drug integrity and patient safety during transit and storage.
Protects clinical flexibility and complex cases. The legislation specifically bars insurers from mandating insurer-designated pharmacy distribution for medications requiring same-day compounding or dosage adjustments based on lab/test results, allowing providers to maintain control over time-sensitive or highly individualized treatments.
Promotes transparency, accreditation, and fair compensation. The bill mandates that insurer-designated pharmacies be nationally accredited, provide medication pedigrees, and offer “site neutral” payments that cover all handling costs for providers, ensuring transparency, accountability, and that facilities are not financially penalized for compliance.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Ensure Safe Medication Delivery
Plain English, a few words. Used as the page title.
Sponsors
1 Co-sponsor
History
- Referred to insurance
- Referred to rules
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Protect Patient Medication Safety
In Assembly Committee · Insurance · Sponsor Linda Rosenthal
Full text
4 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
7252
2021-2022 Regular Sessions
IN SENATE
June 10, 2021
Introduced by Sen. BRESLIN -- read twice and ordered printed, and when printed to be committed to the Committee on Rules
AN ACT to amend the insurance law and the public health law, in relation to establishing patient safety and quality assurance measures regarding the distribution of patient-specific medication from an insurerdesignated pharmacy
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Section 3217-b of the insurance law is amended by adding a new subsection (m) to read as follows:
(m) (1) No insurer subject to this article shall by contract, written policy or written procedure allow or require an insurer-designated pharmacy to dispense a medication directly to a patient with the intention that such patient will transport such medication to a physician's office, hospital or clinic for administration.
(2) An insurer subject to this article may offer coverage for, but shall not require the use of a home infusion pharmacy to dispense sterile intravenous drugs ordered by physicians to patients in their homes or the use of an infusion site external to a patient's provider office or clinic.
(3) An insurer subject to this article, in order to require the distribution of patient-specific medication from an insurer-designated pharmacy to a physician's office, hospital or clinic for administration, shall establish an agreement with the physician, hospital or clinic responsible for receiving and administering such medications to ensure proper receipt, transfer, handling, and storage of the medication prior to administration that includes, but is not limited to, the following provisions:
(A) provide at least ninety days' notice to providers and insurers prior to the implementation of such a requirement;
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD11682-01-1
S. 7252 2
(B) have a patient-specific expedited exception process for cases in which a provider certifies that it is unsafe for a patient to receive medication from an insurer-designated pharmacy;
(C) provide same day delivery of medications;
(D) make available on-call access to a pharmacist or nurse twenty-four hours per day, seven days per week;
(E) utilize cold chain logistics or other means to ensure a drug remains at the appropriate temperature through all stages of supply and storage;
(F) provide a medication's pedigree to certify to the physician's office, hospital or clinic that the drug was handled appropriately through the supply chain;
(G) demonstrate expertise and reliability in risk evaluation and mitigation strategy to comply with United States food and drug administration reporting requirements;
(H) demonstrate the insurer-designated pharmacy is accredited by a national accreditation organization;
(I) demonstrate ability to deliver medications to a physician's office, hospital or clinic in a clinically appropriate dosage and in a ready-to-administer dosage form; and
(J) offer site neutral payment for such medications to the physician's office, hospital or clinic administering the medication, which payment shall include the costs for the providers to intake, store and dispose of such medications.
(4) No insurer subject to this article shall by contract, written policy or written procedure require (A) a medication requiring sterile compounding by the provider, or (B) a medication with a patient-specific dosage requirement to be based upon lab or test results on the day of the patient visit, to be distributed from an insurer-designated pharmacy to a physician's office, hospital or clinic for administration.
§ 2. Section 4325 of the insurance law is amended by adding a new subsection (n) to read as follows:
(n) (1) No corporation organized under this article shall by contract, written policy or written procedure allow or require an insurer-designated pharmacy to dispense a medication directly to a patient with the intention that the patient will transport the medication to a physician's office, hospital or clinic for administration.
(2) A corporation organized under this article may offer coverage for, but shall not require the use of a home infusion pharmacy to dispense sterile intravenous drugs ordered by physicians to patients in their homes or the use of an infusion site external to a patient's provider office or clinic.
(3) A corporation organized under this article, in order to require the distribution of patient-specific medication from an insurer-designated pharmacy to a physician's office, hospital or clinic for administration, shall establish an agreement with the physician, hospital or clinic responsible for receiving and administering such medications to ensure proper receipt, transfer, handling, and storage of the medication prior to administration that includes, but is not limited to, the following provisions:
(A) provide at least ninety days' notice to providers and insureds prior to the implementation of such a requirement;
(B) have a patient-specific expedited exception process for cases in which a provider certifies that it is unsafe for a patient to receive medication from an insurer-designated pharmacy;
(C) provide same day delivery of medications;
S. 7252 3
(D) make available on-call access to a pharmacist or nurse twenty-four hours per day, seven days per week;
(E) utilize cold chain logistics or other means to ensure a drug remains at the appropriate temperature through all stages of supply and storage;
(F) provide a medication's pedigree to certify to the physician's office, hospital or clinic that the drug was handled appropriately through the supply chain;
(G) demonstrate expertise and reliability in risk evaluation and mitigation strategy to comply with United States food and drug administration reporting requirements;
(H) demonstrate the insurer-designated pharmacy is accredited by a national accreditation organization;
(I) demonstrate ability to deliver medications to a physician's office, hospital or clinic in a clinically appropriate dosage and in a ready-to-administer dosage form; and
(J) offer site neutral payment for such medications to the physician's office, hospital or clinic administering the medication, which payment shall include the costs for the providers to intake, store and dispose of such medications.
(4) No corporation organized under this article shall by contract, written policy or written procedure require (A) a medication requiring sterile compounding by the provider, or (B) a medication with a patient-specific dosage requirement to be based upon lab or test results on the day of the patient visit, to be distributed from an insurer-designated pharmacy to a physician's office, hospital or clinic for administration.
§ 3. Section 4406-c of the public health law is amended by adding a new subdivision 11 to read as follows:
11. (a) No health care plan shall by contract or written policy or written procedure allow or require a plan-designated pharmacy to dispense a medication directly to a patient with the intention that the patient will transport the medication to a physician's office, hospital or clinic for administration.
(b) A health care plan may offer coverage for, but shall not require the use of a home infusion pharmacy to dispense sterile intravenous drugs ordered by physicians to patients in their homes or the use of an infusion site external to a patient's provider office or clinic.
(c) A health care plan, in order to require the distribution of patient-specific medication from an insurer-designated pharmacy to a physician's office, hospital or clinic for administration, shall establish an agreement with the physician, hospital or clinic responsible for receiving and administering such medications to ensure proper receipt, transfer, handling, and storage of the medication prior to administration that includes, but is not limited to, the following provisions:
(i) provide at least ninety days' notice to providers and enrollees prior to the implementation of such a requirement;
(ii) have a patient-specific expedited exception process for cases in which a provider certifies that it is unsafe for a patient to receive medication from a plan-designated pharmacy;
(iii) provide same day delivery of medications;
(iv) make available on-call access to a pharmacist or nurse twentyfour hours per day, seven days per week;
(v) utilize cold chain logistics or other means to ensure a drug remains at the appropriate temperature through all stages of supply and storage;
S. 7252 4
(vi) provide a medication's pedigree to certify to the physician's office, hospital or clinic that the drug was handled appropriately through the supply chain;
(vii) demonstrate expertise and reliability in risk evaluation and mitigation strategy to comply with United States food and drug administration reporting requirements;
(viii) demonstrate the insurer-designated pharmacy is accredited by a national accreditation organization;
(ix) demonstrate ability to deliver medications to a physician's office, hospital or clinic in a clinically appropriate dosage and in a ready-to-administer dosage form; and
(x) offer site neutral payment for such medications to the physician's office, hospital or clinic administering the medication, which payment shall include the costs for the providers to intake, store and dispose of such medications.
(d) No health care plan shall by contract, written policy or written procedure require (i) a medication requiring sterile compounding by a provider, or (ii) a medication with a patient-specific dosage requirement to be based upon lab or test results on the day of the patient visit, to be distributed from a plan-designated pharmacy to a physician's office, hospital or clinic for administration.
§ 4. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the insurance law and the public health law, in relation to establishing patient safety and quality assurance measures regarding the distribution of patient-specific medication from an insurer-desig- nated pharmacy
Purpose or general idea of bill
The purpose of this legislation is to improve patient safety and quality assurance associated with health plan policies requiring the use of a designated pharmacy to dispense a specialty drug intended for adminis- tration by a clinician. These policies are commonly referred to as "white bagging" and "brown bagging."
Summary of specific provisions
This bill would amend §§ 3217-b and 4325 of the insurance law and § 4406-c of the public health law to ensure quality assurance and patient safety regarding policies known as white and brown bagging of specialty drugs.
Read the full memo (795 words)
The bill would:
Prohibit a health insurer from requiring the use of an insurer-designat- ed pharmacy to dispense a drug directly to a patient with the intention that the patient will transport the medication to a physician's office, hospital or clinic for administration. This is type of policy is also known "brown bagging."
Authorize an insurer to offer coverage for, but not require, the use of a home infusion pharmacy to dispense intravenous drugs that have been ordered by a physician for administration to a patient at a site other than the patient's provider site.
Prohibit an insurer from requiring the distribution of patient-specific medication from an insurer-designated pharmacy to a physician's office, hospital or clinic (known as "white bagging") unless the insurer has an agreement with the provider that is responsible for receiving and admin- istering the medication that includes specified notice, quality assur- ance and patient safety provisions.
Prohibit "white bagging" policies for medications requiring sterile compounding by a provider or medications with a patient-specific dosage requirement that is based on lab or test results on the day of the patient's visit.
Justification
Increasingly, health insurance plans have begun implementing policies that prohibit a healthcare provider from procuring and managing the handling of a drug used in patient care. Instead the insurer requires the use of an insurer-designated, third-party specialty pharmacy to dispense a specialty drug for administration by a clinician. These poli- cies are commonly referred to as "white bagging" and "brown bagging."
"Brown bagging" policies require a specialty drug to be dispensed by an insurer-designated pharmacy directly to a patient, who then delivers the drug to a clinician for administration. This policy presents numerous chain of custody and patient safety concerns, which were recognized as problematic and as such, prohibited by the NYS Medicaid program in its August 2019 eMed guidance. The guidance states that this practice "caus- es concern regarding proper storage or handling, which can affect the drug efficacy. Brown bagging is not acceptable under NYS Medicaid." This bill would extend and apply this prohibition to all state-regulated insurance plans and policies.
"White bagging" policies also require the use of a third-party, insured-directed pharmacy to dispense a specialty drug. However, in this case, the drug is delivered directly to a hospital pharmacy or physi- cian's office, which then stores the drug until a clinician administers the drug to the patient. Since the provider no longer controls or owns the specialty drug, they cannot verify the source of the medications. Also since they are not responsible for coordinating the delivery and receipt of the drug they are unable to ensure that the drug was stored at the proper temperature prior to arrival at the hospital or clinic, or that the hospital or clinic is ready and able to receive and store products. Unexpected or surprise deliveries create significant, avoid- able challenges related to supply chain and storage capacity that could result in a violation of the individual hospital supply acquisition guidelines.
The NYS Medicaid program also recognizes this "white bagging" policy and deems it acceptable only under specific guidelines addressing concerns related to responsibility and timeliness of delivery of these drugs to the administering clinician. This bill would extend and expand these guidelines to all state-regulated insurance plans and policies to ensure that comprehensive patient protections and quality assurance measures are in place for all insureds, regardless of their health insurance plan.
The bill would also include additional "white bagging" protections to address patient care implications related to certain drug therapy treat- ments, such as oncology. The bill would prohibit "white bagging" for drugs that require a provider to make real-time medication adjustments based on necessary, same day lab and test results. This important patient-protection would prevent unnecessary delays in treatment, which could increase patient risk and adversely affect the patient's treat- ment.
Prior legislative history
New bill.
Fiscal implications
None to the state.
Effective date
This act shall take effect immediately.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.